D&D Pharmatech (XKRX:347850) FCF Margin % : -114.46% (As of Dec. 2023)

View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. D&D Pharmatech's Free Cash Flow for the three months ended in Dec. 2023 was ₩-2,067 Mil. D&D Pharmatech's Revenue for the three months ended in Dec. 2023 was ₩1,805 Mil. Therefore, D&D Pharmatech's FCF Margin % for the quarter that ended in Dec. 2023 was -114.46%.

As of today, D&D Pharmatech's current FCF Yield % is -0.72%.

The historical rank and industry rank for D&D Pharmatech's FCF Margin % or its related term are showing as below:

XKRX:347850' s FCF Margin % Range Over the Past 10 Years
Min: -8811.85 Med: -2321.75 Max: -49.06
Current: -114.46

During the past 6 years, the highest FCF Margin % of D&D Pharmatech was -49.06%. The lowest was -8811.85%. And the median was -2321.75%.

XKRX:347850's FCF Margin % is ranked better than
52.55% of 1039 companies
in the Biotechnology industry
Industry Median: -138.52 vs XKRX:347850: -114.46

D&D Pharmatech FCF Margin % Historical Data

The historical data trend for D&D Pharmatech's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech FCF Margin % Chart

D&D Pharmatech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-3,970.63

-8,811.85

-49.06

D&D Pharmatech Quarterly Data
	Dec22	Sep23	Dec23
FCF Margin %	-8,158.70	-	-114.46

Competitive Comparison of D&D Pharmatech's FCF Margin %

For the Biotechnology subindustry, D&D Pharmatech's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

D&D Pharmatech's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's FCF Margin % distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's FCF Margin % falls into.

D&D Pharmatech FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

D&D Pharmatech's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-9162.629	/	18677.046
	=	-49.06 %

D&D Pharmatech's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-2066.512	/	1805.432
	=	-114.46 %

D&D Pharmatech FCF Margin % Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

D&D Pharmatech (XKRX:347850) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR

Website

http://www.ddpharmatech.com

D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines